Dr. Takeshi Yoshimoto – Cancer – Best Researcher Award

Posted on by Innovator Awards

Dr. Takeshi Yoshimoto - Cancer - Best Researcher Award

University of Tsukuba Hospital - Japan

Author Profile

SCOPUS

🎓 Early academic pursuits

 Dr. Takeshi Yoshimoto began his academic journey in the medical sciences with a strong foundation in clinical education. he earned his m.d. from hiroshima university faculty of medicine in march 2008, followed by a ph.d. from the graduate school of biomedical and health sciences, hiroshima university in august 2022. during his formative years, his curiosity about cerebrovascular diseases led him to explore genetics, biomarkers, and translational medicine, laying the groundwork for his future research focus, which indirectly intersects with diagnostic technologies resembling the precision systems used in power electronics.

🧠 Professional endeavors

Dr. Yoshimoto's career showcases a rich progression through esteemed institutions. from his early role as an intern at fukushima coop hospital, he gradually ascended through ranks at national cerebral and cardiovascular center, serving as resident, senior resident, Cancer and later as a medical doctor under  distinguished mentors like dr. ihara and dr. toyoda. he also contributed to academia at hiroshima university and currently serves as a lecturer in the department of stroke and cerebrovascular diseases at university of tsukuba hospital. his consistent clinical involvement paired with academic appointments underlines his dual commitment to patient care and neurological research.

🧬 Contributions and research focus

A pioneer in translational stroke research, dr. yoshimoto focuses on integrating genetics with acute stroke management. his primary research involves developing algorithms for selecting clot removal devices by identifying genetic variations, particularly the moyamoya-related rnf213 p.r4810k polymorphism. he explores the association between juvenile strokes and serum biomarkers. his projects are comparable in Cancer precision and application-oriented design to power electronics, highlighting his innovative integration of medical diagnostics and genetic profiling to improve acute care strategies.

🌍 Impact and influence

Dr. Yoshimoto’s work has had significant impact on cerebrovascular research, especially in japan. his dedication to exploring the genetic underpinnings of stroke has advanced understanding of moyamoya disease and enhanced patient stratification for endovascular therapy. his influence is also evident in the repeated recognition he received at prestigious national and international conferences, positioning him as a leading voice Cancer in neurovascular translational research. the framework he established for genetic-based intervention selection has potential parallels with feedback and adaptive systems in power electronics, reflecting the precision and personalization he brings to neurology.

🏆 Academic cites and recognition

Dr. Yoshimoto’s excellence has been widely acknowledged. he received the paul dudley white international scholar award from the american heart association in 2021 and multiple presentation awards at the japan stroke society and japanese society of neuroendovascular therapy (jsnet). notably, he received teaching awards and outstanding paper honors, reinforcing his role Cancer as both a scholar and mentor. these accolades validate the academic rigor and practical relevance of his work, particularly his contributions to stroke genetics and device selection.

🔬 Legacy and future contributions

Dr. Yoshimoto is poised to continue shaping the future of stroke research with a strong emphasis on personalized medicine. he aims to refine and implement his clot removal device selection algorithm into broader clinical practice. further integration of genetic biomarkers into real-time therapeutic decision-making is expected. his work not only improves outcomes for stroke patients but also sets a model for interdisciplinary research convergence, similar to how power electronics evolved by merging physics, control theory, and electrical engineering.

Notable Publication

  • Title: Relationship Between RNF213 p.R4810K and Echocardiographic Findings in Patients with Cerebrovascular Diseases: A Multicenter Prospective Cohort Study
    Author(s): Kotaro Noda, Yorito Hattori, Tatsuya Nishii, Yoshikazu Nakaoka, Masafumi Ihara
    Journal: Journal of the American Heart Association, 2025

  • Title: Deep learning-based post hoc denoising for 3D volume-rendered cardiac CT in mitral valve prolapse
    Author(s): Tatsuya Nishii, Tomoro Morikawa, Hiroki Nakajima, Satsuki M. Fukushima, Tetsuya Fukuda
    Journal: International Journal of Cardiovascular Imaging, 2025

  • Title: Evaluation of the Efficacy and Accuracy of Super-Flexible Three-Dimensional Heart Models of Congenital Heart Disease Made via Stereolithography Printing and Vacuum Casting: A Multicenter Clinical Trial
    Author(s): Isao Shiraishi, Masaaki Yamagishi, Takaya Hoashi, Toshiaki Hisada, Kenichi Kurosaki
    Journal: Journal of Cardiovascular Development and Disease, 2024

  • Title: Pericardial adhesion and performance of hemodynamically significant constrictive pericarditis using cine magnetic resonance feature tracking
    Author(s): Yasutoshi Ohta, Midori Fukuyama, Yoshiaki Morita, Hiroki Horinouchi, Tetsuya Fukuda
    Journal: International Journal of Cardiovascular Imaging, 2024

  • Title: Laterality of CT-measured hepatic extracellular volume fraction in patients with chronic thromboembolic pulmonary hypertension
    Author(s): Tatsuya Nishii, Hiroki Horinouchi, Takara Namboku, Takeshi Ogo, Tetsuya Fukuda
    Journal: International Journal of Cardiovascular Imaging, 2024

  • Title: Covering the intercostal artery branching of the Adamkiewicz artery during endovascular aortic repair increases the risk of spinal cord ischemia
    Author(s): Yoshimasa Seike, Tatsuya Nishii, Kazufumi Yoshida, Tetsuya Fukuda, Hitoshi Matsuda
    Journal: JTCVS Open, 2024

Dr. Evgenii Shumilov – Oncology and Hematology – Outstanding Scientist Award

Posted on by Innovator Awards

Dr. Evgenii Shumilov - Oncology and Hematology - Outstanding Scientist Award

University Hospital Münster Medical Clinic A -  Germany

Author Profile 

ORCID 

🎓 Early academic pursuits

Dr. Evgenii Shumilov began his academic journey in kirovskaya gebiet, russland, where he completed his general secondary education in june 2006. driven by a passion for human biology and clinical care, he enrolled in the staatliche medizinische akademie in kirow in 2006. the following year, he transitioned to the esteemed st. petersburger staatliche medizinische universität i.p. pawlow, where he pursued his degree in human medicine until 2012. during this formative period, he developed a growing interest in the biochemical pathways influencing addiction, which would later shape his doctoral research.

🏥 Professional endeavors

His professional career started immediately after his graduation with a clinical internship in internal medicine at the universitätsklinikum st. petersburg i.p. pawlow. dr. shumilov then completed a specialized clinical training in oncology at the renowned n.n. petrow institute for oncology. from 2015 to 2021, he continued his facharztausbildung (specialist training) in internal medicine, hematology, and oncology at the universitätsmedizin göttingen. since 2021, he has served in various capacities at the universitätsklinikum münster, advancing to oberarzt (senior physician) in the day clinic of oncology by 2022. his role requires the coordination of clinical therapies, implementation of modern diagnostics, and integration of interdisciplinary care — akin to the precision and optimization seen in power electronics systems.

🔬 Contributions and research focus

Dr. Shumilov has made significant scientific contributions in the field of pharmacology and hemato-oncology. between 2012 and 2015, he pursued a doctoral program in pharmacology at the anichkow institute for experimental medicine, focusing on neuropharmacology and the role of orexin-1 receptors in addiction — a study that mirrors the regulatory mechanisms of feedback and control in power electronics. in 2018, he earned a second doctorate (dr. med.) from the university of bern, switzerland, with a dissertation exploring genetic mutations bridging Oncology and Hematology hematopoietic lineages and solid tumors in the age of high-throughput sequencing. his work has helped redefine diagnostic paradigms in clinical oncology.

🌍 Impact and influence

Dr. Shumilov’s cross-disciplinary expertise bridges clinical practice and molecular diagnostics. his innovative thinking, reflected in his dual doctoral research and international academic Oncology and Hematology exposure, positions him as a leader in precision medicine. like the transformative role of power electronics in renewable energy systems, his influence lies in optimizing diagnostic accuracy and tailoring therapies for oncology patients. he is actively mentoring junior clinicians, integrating translational research into routine care, and contributing to academic networks across europe and russia.

📚 Academic citations and recognitions

He has received notable academic recognition, including a posterpreis at the dgho annual meeting in stuttgart (2017), and the prestigious dfg “clinician scientist” funding from 2020 to 2021. his scientific contributions are frequently cited in studies on neuropharmacology and next-generation sequencing diagnostics. his work on orexin receptors and hematologic malignancies Oncology and Hematology continues to influence both pharmacologic models and clinical protocols.

🌱 Legacy and future contributions

Dr. Shumilov’s legacy lies in his capacity to interweave basic science with clinical oncology. he is currently leading projects that integrate high-throughput genomic data with patient-specific therapy plans, aiming for breakthroughs in hematologic and solid tumor treatments. with a forward-looking perspective, he is exploring digital integration and ai-assisted diagnostics, similar to how power electronics revolutionize control in automated systems. his future vision includes strengthening international research collaborations and expanding educational programs for medical scientists.

Notable Publications 

  • Title: Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed/refractory large B-cell lymphoma
    Author(s): Evgenii Shumilov, Julia Katharina Scholz, Maximilian Seib, Paolo Mazzeo, Rebecca Wurm-Kuczera, Vladan Vucinic, Udo Holtick, Hristo Boyadzhiev, Thomas Melchardt, Alexander Sebastian Hölscher, et al.
    Journal: Blood Advances

  • Title: Allogeneic stem cell transplantation against aggressive lymphomas: graft-versus-lymphoma effects in peripheral T-cell lymphoma and diffuse large B-cell lymphoma after myeloablative conditioning
    Author(s): Evgenii Shumilov, Lena Levien, Paolo Mazzeo, Wolfram Jung, Andreas Leha, Raphael Koch, Justin Hasenkamp, Gerald Wulf
    Journal: Leukemia & Lymphoma

  • Title: Safety and Efficacy of Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma in a Multinational Real-World Study
    Author(s): Evgenii Shumilov, Rebecca Wurm-Kuczera, Andrea Kerkhoff, Meng Wang, Thomas Melchardt, Udo Holtick, Ulrike Bacher, Philipp B. Staber, Paolo Mazzeo, Corinna Leng, et al.
    Journal: Blood Advances

  • Title: Benefit of repeated COVID‐19 vaccination for patients with B‐cell malignancies
    Author(s): Ulrike Bacher, Evgenii Shumilov, Thomas Pabst
    Journal: British Journal of Haematology

  • Title: Radiotherapy in Combination with Systemic Therapy for Multiple Myeloma—A Critical Toxicity Evaluation in the Modern Treatment Era
    Author(s): Michael Oertel, Tom Schlusemann, Evgenii Shumilov, Gabriele Reinartz, Anne Bremer, Stephan Rehn, Georg Lenz, Cyrus Khandanpour, Hans Theodor Eich
    Journal: Cancers

Dr. Melania Tesio – Oncologia –  Best Researcher Award

Posted on by Innovator Awards

Dr. Melania Tesio - Oncologia -  Best Researcher Award

INSERM - France

Author Profile 

SCOPUS 

🎓 Early academic pursuits

Melania Tesio embarked on her academic journey with a solid foundation in medical biotechnology, earning her degree with full honors from the university of torino, italy, in 2002. her passion for oncology led her to pursue a doctoral degree, culminating in a ph.d. in human oncology in 2007. her studies were uniquely enriched by a dual affiliation with the university of torino and the weizmann institute of science, israel, where she collaborated on groundbreaking research projects that laid the groundwork for her future contributions to cancer research.

🧪 Professional endeavors

Following her ph.d., Melania transitioned into impactful research roles. from 2007 to 2008, she worked as a postdoctoral researcher at the weizmann institute of science under prof. tsvee lapidot, where she delved into hematopoietic and immune system dynamics. subsequently, she joined the german cancer research center (dkfz) in 2008, collaborating with prof. andreas trumpp until 2014. since 2017, she has been a researcher at inserm, contributing significantly to unit u1111, lyon, france, where she focuses on translational cancer research while balancing her roles during maternity leave and part-time work.

🔬 Contributions and research focus

Melania's research has consistently centered on understanding the molecular mechanisms underpinning cancer, particularly t-cell acute lymphoblastic leukemia (t-all). her studies have uncovered critical insights into metabolic rewiring induced by genetic abnormalities, such as pten loss. she has also contributed to elucidating Oncologia the molecular blueprints of thymopoiesis and enhancer activation in tcr development. her recent work as a senior researcher has focused on the intersection of metabolism and oncogenesis, driving innovative therapeutic strategies for blood cancers.

🏆 Accolades and recognition

Melania’s contributions have been widely recognized in the scientific community. with an h-index of 19 and over 2,800 citations, her work has significantly impacted Oncologia cancer biology. she has been the last and corresponding author on prestigious publications, showcasing her leadership in collaborative research. her groundbreaking findings have been published in high-impact journals like blood advances, leukemia, and j experimental medicine, further establishing her as a thought leader in oncology research.

🌟 Impact and influence

Through her pioneering research, melania has advanced the understanding of key biological pathways in leukemia, offering new avenues for therapeutic Oncologia interventions. her work on age-related clinical features of pten abnormalities in t-all and molecular mechanisms of tcr enhancer activation has provided valuable frameworks for clinical applications. as a mentor, she has inspired the next generation of researchers, fostering a culture of innovation and collaboration.

🌍 Legacy and future contributions

Melania’s legacy is deeply rooted in her commitment to translational oncology, where she bridges the gap between fundamental research and clinical applications. looking ahead, she aims to expand her research into metabolic dependencies in cancer, paving the way for precision medicine approaches. her dedication to unraveling complex biological systems continues to shape the field of cancer research, ensuring lasting contributions to scientific progress and patient care.

Notable Publications 

  • Title: Tell me who you go with and I'll tell you who you are
    Author: M. Tesio
    Journal: HemaSphere, 2024, 8(1), e36
  • Title: Editorial: Tyrosine kinases and phosphatases in T-cell malignancies
    Author: M. Tesio
    Journal: Frontiers in Oncology, 2024, 14, 1372133
  • Title: Sunscreen to Protect the Marrow
    Author: M. Tesio
    Journal: HemaSphere, 2023, 7(9), pp. E941
  • Title: Mitigating the Risk of t-MNs Development: TP53 or Not TP53?
    Author: M. Tesio
    Journal: HemaSphere, 2023, 7(2), pp. E827
  • Title: Reporting From the First EHA Research Conference: Exciting Science With Panoramic Views
    Author: M. Tesio
    Journal: HemaSphere, 2023, 7(1), pp. E816